Aura Biosciences, Inc. AURA

AURA Company Overview

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors using its proprietary Virus-Like Drug Conjugate (VDC) platform. The company operates within the biotechnology and oncology sectors, with an emphasis on ophthalmic oncology and other solid tumor indications. Aura’s lead product candidate, bel-sar (formerly AU-011), is being developed primarily for the treatment of early-stage choroidal melanoma, a rare and potentially vision-threatening ocular cancer. The company’s platform is designed to selectively target tumor cells while minimizing damage to surrounding healthy tissue through light-activated therapeutic mechanisms.

The company was founded in 2009 and has evolved from an early-stage platform research company into a publicly traded biotechnology firm listed on Nasdaq under the ticker AURA. Aura’s strategic positioning is tied to its proprietary VDC technology, which combines virus-like particles with cytotoxic agents to create targeted therapies intended to improve efficacy and safety profiles compared with conventional oncology treatments. The company’s research focus has expanded beyond ocular oncology into broader solid tumor applications, though its primary clinical emphasis remains centered on ocular cancers.